Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 371

1.

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.

Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Fecker J, Model F, Wei W, Arnold DL.

Brain. 2019 Sep 1;142(9):2787-2799. doi: 10.1093/brain/awz212.

PMID:
31497864
2.

Telomere length is associated with disability progression in multiple sclerosis.

Krysko KM, Henry RG, Cree BAC, Lin J; UCSF MS-EPIC Team, Caillier S, Santaniello A, Zhao C, Gomez R, Bevan C, Smith DL, Stern W, Kirkish G, Hauser SL, Oksenberg JR, Graves JS.

Ann Neurol. 2019 Sep 4. doi: 10.1002/ana.25592. [Epub ahead of print]

PMID:
31486104
3.

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.

Barkhof F, Kappos L, Wolinsky JS, Li DKB, Bar-Or A, Hartung HP, Belachew S, Han J, Julian L, Sauter A, Napieralski J, Koendgen H, Hauser SL.

Neurology. 2019 Sep 4. pii: 10.1212/WNL.0000000000008189. doi: 10.1212/WNL.0000000000008189. [Epub ahead of print]

PMID:
31484710
4.

Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study.

Midaglia L, Mulero P, Montalban X, Graves J, Hauser SL, Julian L, Baker M, Schadrack J, Gossens C, Scotland A, Lipsmeier F, van Beek J, Bernasconi C, Belachew S, Lindemann M.

J Med Internet Res. 2019 Aug 30;21(8):e14863. doi: 10.2196/14863.

5.

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years.

Cantó E, Barro C, Zhao C, Caillier SJ, Michalak Z, Bove R, Tomic D, Santaniello A, Häring DA, Hollenbach J, Henry RG, Cree BAC, Kappos L, Leppert D, Hauser SL, Benkert P, Oksenberg JR, Kuhle J.

JAMA Neurol. 2019 Aug 12. doi: 10.1001/jamaneurol.2019.2137. [Epub ahead of print]

PMID:
31403661
6.

Opposing T cell responses in experimental autoimmune encephalomyelitis.

Saligrama N, Zhao F, Sikora MJ, Serratelli WS, Fernandes RA, Louis DM, Yao W, Ji X, Idoyaga J, Mahajan VB, Steinmetz LM, Chien YH, Hauser SL, Oksenberg JR, Garcia KC, Davis MM.

Nature. 2019 Aug;572(7770):481-487. doi: 10.1038/s41586-019-1467-x. Epub 2019 Aug 7.

PMID:
31391585
7.

Reply to "Silent Progression or Bout Onset Progressive Multiple Sclerosis?"

Cree BAC, Hauser SL.

Ann Neurol. 2019 Sep;86(3):472-473. doi: 10.1002/ana.25536. Epub 2019 Jul 12. No abstract available.

PMID:
31251816
8.

Nucleic Acid-Based Therapeutics Relevant to Neuroimmune Conditions.

Greenfield AL, Hauser SL.

Neurotherapeutics. 2019 Apr;16(2):314-318. doi: 10.1007/s13311-019-00740-5. Review. No abstract available.

PMID:
31087242
9.

Sex-specific Tau methylation patterns and synaptic transcriptional alterations are associated with neural vulnerability during chronic neuroinflammation.

Didonna A, Cantó E, Shams H, Isobe N, Zhao C, Caillier SJ, Condello C, Yamate-Morgan H, Tiwari-Woodruff SK, Mofrad MRK, Hauser SL, Oksenberg JR.

J Autoimmun. 2019 Jul;101:56-69. doi: 10.1016/j.jaut.2019.04.003. Epub 2019 Apr 19.

PMID:
31010726
10.

A specific amino acid motif of HLA-DRB1 mediates risk and interacts with smoking history in Parkinson's disease.

Hollenbach JA, Norman PJ, Creary LE, Damotte V, Montero-Martin G, Caillier S, Anderson KM, Misra MK, Nemat-Gorgani N, Osoegawa K, Santaniello A, Renschen A, Marin WM, Dandekar R, Parham P, Tanner CM, Hauser SL, Fernandez-Viña M, Oksenberg JR.

Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7419-7424. doi: 10.1073/pnas.1821778116. Epub 2019 Mar 25.

11.

Silent progression in disease activity-free relapsing multiple sclerosis.

University of California, San Francisco MS-EPIC Team, Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, Bischof A, Gundel T, Zhu AH, Papinutto N, Stern WA, Bevan C, Romeo A, Goodin DS, Gelfand JM, Graves J, Green AJ, Wilson MR, Zamvil SS, Zhao C, Gomez R, Ragan NR, Rush GQ, Barba P, Santaniello A, Baranzini SE, Oksenberg JR, Henry RG, Hauser SL.

Ann Neurol. 2019 May;85(5):653-666. doi: 10.1002/ana.25463. Epub 2019 Mar 30.

12.

Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.

Mayer L, Kappos L, Racke MK, Rammohan K, Traboulsee A, Hauser SL, Julian L, Köndgen H, Li C, Napieralski J, Zheng H, Wolinsky JS.

Mult Scler Relat Disord. 2019 May;30:236-243. doi: 10.1016/j.msard.2019.01.044. Epub 2019 Jan 28.

PMID:
30844611
13.

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.

Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS, Buffels R, Fiore D, Garren H, Han J, Hauser SL.

J Neurol. 2019 May;266(5):1182-1193. doi: 10.1007/s00415-019-09248-6. Epub 2019 Feb 28.

14.

Longitudinally persistent cerebrospinal fluid B cells can resist treatment in multiple sclerosis.

Greenfield AL, Dandekar R, Ramesh A, Eggers EL, Wu H, Laurent S, Harkin W, Pierson NS, Weber MS, Henry RG, Bischof A, Cree BA, Hauser SL, Wilson MR, von Büdingen HC.

JCI Insight. 2019 Mar 21;4(6). pii: 126599. doi: 10.1172/jci.insight.126599. eCollection 2019 Mar 21.

15.

pRNFL as a marker of disability worsening in the medium/long term in patients with MS.

Cordano C, Nourbakhsh B, Devereux M, Damotte V, Bennett D, Hauser SL, Cree BAC, Gelfand JM, Green AJ.

Neurol Neuroimmunol Neuroinflamm. 2018 Dec 21;6(2):e533. doi: 10.1212/NXI.0000000000000533. eCollection 2019 Mar. No abstract available.

16.

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.

Elliott C, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Wei W, Belachew S, Arnold DL.

Mult Scler. 2018 Dec 19:1352458518814117. doi: 10.1177/1352458518814117. [Epub ahead of print]

PMID:
30566027
17.

Body mass index, but not vitamin D status, is associated with brain volume change in MS.

Mowry EM, Azevedo CJ, McCulloch CE, Okuda DT, Lincoln RR, Waubant E, Hauser SL, Pelletier D.

Neurology. 2018 Dec 11;91(24):e2256-e2264. doi: 10.1212/WNL.0000000000006644. Epub 2018 Nov 14.

PMID:
30429274
18.

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.

Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L.

Ann Neurol. 2018 Oct;84(4):527-536. doi: 10.1002/ana.25313.

19.

Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.

Bove R, Bevan C, Crabtree E, Zhao C, Gomez R, Garcha P, Morrissey J, Dierkhising J, Green AJ, Hauser SL, Cree BA, Wallin MT, Gelfand JM.

Mult Scler. 2018 Aug 24:1352458518793527. doi: 10.1177/1352458518793527. [Epub ahead of print]

PMID:
30141729
20.

Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.

Jia X, Madireddy L, Caillier S, Santaniello A, Esposito F, Comi G, Stuve O, Zhou Y, Taylor B, Kilpatrick T, Martinelli-Boneschi F, Cree BAC, Oksenberg JR, Hauser SL, Baranzini SE.

Ann Neurol. 2018 Jul;84(1):51-63. doi: 10.1002/ana.25263. Epub 2018 Jul 3.

21.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G.

Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.

22.

Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD.

Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, Green AJ, Hauser SL, Bove R.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 19;5(3):e453. doi: 10.1212/NXI.0000000000000453. eCollection 2018 May.

23.

Multiple Sclerosis: B Cells Take Center Stage.

Pröbstel AK, Hauser SL.

J Neuroophthalmol. 2018 Jun;38(2):251-258. doi: 10.1097/WNO.0000000000000642. Review. No abstract available.

24.

Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients.

Canto E, Isobe N, Didonna A; MS-EPIC Study Group, Hauser SL, Oksenberg JR.

J Neuroinflammation. 2018 Mar 7;15(1):72. doi: 10.1186/s12974-018-1105-9.

25.

B-Cell Therapies in Multiple Sclerosis.

Sabatino JJ Jr, Zamvil SS, Hauser SL.

Cold Spring Harb Perspect Med. 2019 Feb 1;9(2). pii: a032037. doi: 10.1101/cshperspect.a032037. Review.

PMID:
29358322
26.

Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease.

Azevedo CJ, Cen SY, Khadka S, Liu S, Kornak J, Shi Y, Zheng L, Hauser SL, Pelletier D.

Ann Neurol. 2018 Feb;83(2):223-234. doi: 10.1002/ana.25150. Epub 2018 Feb 9.

27.

Harnessing electronic medical records to advance research on multiple sclerosis.

Damotte V, Lizée A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, Gomez R, Lincoln R, Tang W, Chen T, Lee N, Villoslada P, Hollenbach JA, Bevan CD, Graves J, Bove R, Goodin DS, Green AJ, Baranzini SE, Cree BA, Henry RG, Hauser SL, Gelfand JM, Gourraud PA.

Mult Scler. 2019 Mar;25(3):408-418. doi: 10.1177/1352458517747407. Epub 2018 Jan 9.

PMID:
29310490
28.

Diagnosing multiple sclerosis: art and science.

Bove RM, Hauser SL.

Lancet Neurol. 2018 Feb;17(2):109-111. doi: 10.1016/S1474-4422(17)30461-1. Epub 2017 Dec 21. No abstract available.

PMID:
29275980
29.

Ovarian aging is associated with gray matter volume and disability in women with MS.

Graves JS, Henry RG, Cree BAC, Lambert-Messerlian G, Greenblatt RM, Waubant E, Cedars MI, Zhu A; University of California, San Francisco MS-EPIC Team,, Bacchetti P, Hauser SL, Oksenberg JR.

Neurology. 2018 Jan 16;90(3):e254-e260. doi: 10.1212/WNL.0000000000004843. Epub 2017 Dec 22.

30.

B-cell Therapy for Multiple Sclerosis: Entering an era.

Greenfield AL, Hauser SL.

Ann Neurol. 2018 Jan;83(1):13-26. doi: 10.1002/ana.25119. Review.

31.

Advances in Imaging Multiple Sclerosis.

Bischof A, Caverzasi E, Cordano C, Hauser SL, Henry RG.

Semin Neurol. 2017 Oct;37(5):538-545. doi: 10.1055/s-0037-1607278. Epub 2017 Dec 5. Review. No abstract available.

PMID:
29207413
32.

Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients.

Eggers EL, Michel BA, Wu H, Wang SZ, Bevan CJ, Abounasr A, Pierson NS, Bischof A, Kazer M, Leitner E, Greenfield AL, Demuth S, Wilson MR, Henry RG, Cree BA, Hauser SL, von Büdingen HC.

JCI Insight. 2017 Nov 16;2(22). pii: 92724. doi: 10.1172/jci.insight.92724. eCollection 2017 Nov 16.

33.

Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.

Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, Koth LL, Hauser SL, Dierkhising J, Vu N, Sriram S, Moses H, Bagnato F, Kaufmann JA, Ammah DJ, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S.

Neurology. 2017 Nov 14;89(20):2092-2100. doi: 10.1212/WNL.0000000000004644. Epub 2017 Oct 13.

34.

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.

Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, Nobuta H, Zhu A, Friessen M, Gerona R, von Büdingen HC, Henry RG, Hauser SL, Chan JR.

Lancet. 2017 Dec 2;390(10111):2481-2489. doi: 10.1016/S0140-6736(17)32346-2. Epub 2017 Oct 10.

35.

Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models.

Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, Crabtree-Hartman E, Sand IK, Gacias M, Zhu Y, Casaccia P, Cree BAC, Knight R, Mazmanian SK, Baranzini SE.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10713-10718. doi: 10.1073/pnas.1711235114. Epub 2017 Sep 11. Erratum in: Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):E8943.

36.

SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.

Bove R, Chitnis T, Cree BA, Tintoré M, Naegelin Y, Uitdehaag BM, Kappos L, Khoury SJ, Montalban X, Hauser SL, Weiner HL; SUMMIT Consortium.

Mult Scler. 2018 Oct;24(11):1485-1498. doi: 10.1177/1352458517726657. Epub 2017 Aug 29.

PMID:
28847219
37.

Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.

Gelfand JM, Cree BAC, Hauser SL.

Neurotherapeutics. 2017 Oct;14(4):835-841. doi: 10.1007/s13311-017-0557-4. Review.

38.

Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.

Hauser SL, Belachew S, Kappos L.

N Engl J Med. 2017 Apr 27;376(17):1694. doi: 10.1056/NEJMc1702076. No abstract available.

PMID:
28445661
39.

Onset of secondary progressive MS after long-term rituximab therapy - a case report.

von Büdingen HC, Bischof A, Eggers EL, Wang S, Bevan CJ, Cree BA, Henry RG, Hauser SL.

Ann Clin Transl Neurol. 2016 Dec 20;4(1):46-52. doi: 10.1002/acn3.377. eCollection 2017 Jan.

40.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

41.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

42.

Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedström A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Søndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, D'Alfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF.

Neurol Genet. 2016 Aug 4;2(4):e87. doi: 10.1212/NXG.0000000000000087. eCollection 2016 Aug.

43.

Long-term evolution of multiple sclerosis disability in the treatment era.

University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL.

Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.

44.

Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis.

Isobe N, Keshavan A, Gourraud PA, Zhu AH, Datta E, Schlaeger R, Caillier SJ, Santaniello A, Lizée A, Himmelstein DS, Baranzini SE, Hollenbach J, Cree BA, Hauser SL, Oksenberg JR, Henry RG.

JAMA Neurol. 2016 Jul 1;73(7):795-802. doi: 10.1001/jamaneurol.2016.0980.

45.

Power estimation for non-standardized multisite studies.

Keshavan A, Paul F, Beyer MK, Zhu AH, Papinutto N, Shinohara RT, Stern W, Amann M, Bakshi R, Bischof A, Carriero A, Comabella M, Crane JC, D'Alfonso S, Demaerel P, Dubois B, Filippi M, Fleischer V, Fontaine B, Gaetano L, Goris A, Graetz C, Gröger A, Groppa S, Hafler DA, Harbo HF, Hemmer B, Jordan K, Kappos L, Kirkish G, Llufriu S, Magon S, Martinelli-Boneschi F, McCauley JL, Montalban X, Mühlau M, Pelletier D, Pattany PM, Pericak-Vance M, Cournu-Rebeix I, Rocca MA, Rovira A, Schlaeger R, Saiz A, Sprenger T, Stecco A, Uitdehaag BMJ, Villoslada P, Wattjes MP, Weiner H, Wuerfel J, Zimmer C, Zipp F; International Multiple Sclerosis Genetics Consortium. Electronic address: AIVINSON@PARTNERS.ORG, Hauser SL, Oksenberg JR, Henry RG.

Neuroimage. 2016 Jul 1;134:281-294. doi: 10.1016/j.neuroimage.2016.03.051. Epub 2016 Apr 1.

46.

Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis.

Khankhanian P, Cozen W, Himmelstein DS, Madireddy L, Din L, van den Berg A, Matsushita T, Glaser SL, Moré JM, Smedby KE, Baranzini SE, Mack TM, Lizée A, de Sanjosé S, Gourraud PA, Nieters A, Hauser SL, Cocco P, Maynadié M, Foretová L, Staines A, Delahaye-Sourdeix M, Li D, Bhatia S, Melbye M, Onel K, Jarrett R, McKay JD, Oksenberg JR, Hjalgrim H.

Int J Epidemiol. 2016 Jun;45(3):728-40. doi: 10.1093/ije/dyv364. Epub 2016 Mar 12.

47.

A non-synonymous single-nucleotide polymorphism associated with multiple sclerosis risk affects the EVI5 interactome.

Didonna A, Isobe N, Caillier SJ, Li KH, Burlingame AL, Hauser SL, Baranzini SE, Patsopoulos NA, Oksenberg JR.

Hum Mol Genet. 2015 Dec 15;24(24):7151-8. doi: 10.1093/hmg/ddv412. Epub 2015 Oct 3.

48.

Class II HLA interactions modulate genetic risk for multiple sclerosis.

Moutsianas L, Jostins L, Beecham AH, Dilthey AT, Xifara DK, Ban M, Shah TS, Patsopoulos NA, Alfredsson L, Anderson CA, Attfield KE, Baranzini SE, Barrett J, Binder TMC, Booth D, Buck D, Celius EG, Cotsapas C, D'Alfonso S, Dendrou CA, Donnelly P, Dubois B, Fontaine B, Fugger L, Goris A, Gourraud PA, Graetz C, Hemmer B, Hillert J; International IBD Genetics Consortium (IIBDGC), Kockum I, Leslie S, Lill CM, Martinelli-Boneschi F, Oksenberg JR, Olsson T, Oturai A, Saarela J, Søndergaard HB, Spurkland A, Taylor B, Winkelmann J, Zipp F, Haines JL, Pericak-Vance MA, Spencer CCA, Stewart G, Hafler DA, Ivinson AJ, Harbo HF, Hauser SL, De Jager PL, Compston A, McCauley JL, Sawcer S, McVean G.

Nat Genet. 2015 Oct;47(10):1107-1113. doi: 10.1038/ng.3395. Epub 2015 Sep 7.

49.

Genetic contribution to multiple sclerosis risk among Ashkenazi Jews.

Khankhanian P, Matsushita T, Madireddy L, Lizée A, Din L, Moré JM, Gourraud PA, Hauser SL, Baranzini SE, Oksenberg JR.

BMC Med Genet. 2015 Jul 28;16:55. doi: 10.1186/s12881-015-0201-2.

50.

Mitochondrial DNA sequence variation in multiple sclerosis.

Tranah GJ, Santaniello A, Caillier SJ, D'Alfonso S, Martinelli Boneschi F, Hauser SL, Oksenberg JR.

Neurology. 2015 Jul 28;85(4):325-30. doi: 10.1212/WNL.0000000000001744. Epub 2015 Jul 1.

Supplemental Content

Loading ...
Support Center